As of October 9, 2026, retatrutide is Lilly’s investigational medicine being studied for adult obesity and type 2 diabetes. It is not FDA-approved or available for routine prescribing.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Retatrutide is being studied as a GIP, GLP-1, and glucagon receptor agonist. Trial findings are not an individualized safety assessment.
As of October 9, 2026, retatrutide is Lilly’s investigational medicine being studied for adult obesity and type 2 diabetes. It is not FDA-approved or available for routine prescribing. Access is limited to eligible participants in Lilly’s clinical trials. For treatment now, a clinician can review currently approved options for your diagnosis and goals.
Retatrutide is a single investigational molecule that activates three receptors: GIP, GLP-1 and glucagon. It is therefore a triple receptor agonist, rather than a GLP-1-only medicine. Lilly is studying effects on weight and blood-glucose control in clinical trials. These research targets do not establish approved treatment benefits or show that it is suitable for you. There is no FDA-approved retatrutide product for routine care.
Trial eligibility is determined by the specific protocol and study team. A person may still be evaluated for currently approved diabetes or weight-management care. Study participation is not guaranteed and must not require stopping prescribed treatment without a plan.
Check the manufacturer’s current development update and an official ClinicalTrials.gov record. Confirm the recruiting site through the listed study contact, eligibility, consent process, and follow-up obligations. For care now, discuss approved options and their risks with a clinician. Online research-use peptides are not an approved retatrutide product.
Bring your diagnosis, weight and medicine history, relevant tests, and the exact trial record if you want to discuss research participation. Confirm trial status and location directly with the study team.
Do not buy research-use peptides or recreate combinations yourself. Product identity, concentration, quality, and safety may be uncertain. Contact the study team listed in the official trial record to discuss research access.
A legitimate study uses its protocol, monitoring, and adverse-event contact process. Routine clinical care and refills remain important while you consider research. New trial results do not establish safety or benefit for an individual.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
The investigational mechanism and study results can inform research, but they do not establish routine prescribing or superiority for you. Currently approved weight medicines have product-specific indications, risks, and monitoring. Review approved options with the clinician while checking the study’s status.
No. An announcement can report study results, enrollment, or an application. Each is separate from FDA approval, a pharmacy launch, insurance coverage, and a Nao Medical service. Retatrutide remains investigational as of October 12, 2026 and is not FDA-approved for routine treatment. Manufacturer news and study enrollment are separate from FDA approval and pharmacy availability.
Trial enrollment is handled by the recruiting study team. Ask the recruiting study team through the official trial record about eligibility and location. A routine clinical appointment does not guarantee enrollment. Continue prescribed care while discussing trial participation.
No. Retatrutide is investigational and is not an FDA-approved medicine available from an ordinary pharmacy. FDA states that retatrutide cannot be used in compounding under federal law. Do not buy or inject an online product labeled “research use” or sold as compounded retatrutide. Legitimate access is through an eligible Lilly-sponsored clinical trial and its study team. For care now, discuss approved weight-management or diabetes options with a clinician. A routine Nao appointment does not guarantee trial enrollment.
Use an official ClinicalTrials.gov record and the manufacturer’s trial information. Check the study’s current recruitment status, location, eligibility, contact details, and consent process directly with the listed study team. A promotional post or an online product listing is not a trial enrollment route.
No. Trial averages and reported adverse events cannot determine your individual suitability. Study participants meet a protocol and receive monitoring. A clinician must review your conditions and medicines, and investigational treatment belongs within legitimate research.
There are no FDA-approved retatrutide self-injection instructions. As of October 9, 2026, it remains investigational. In a Lilly-sponsored trial, the study team determines the product, administration and monitoring under the protocol. Do not inject a research-use or online peptide product or copy an experimental injection plan. For treatment now, discuss approved weight-management or diabetes medicines with a clinician.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
